Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
After several decades of intense clinical research, the great promise of Type I interferons (IFN1) as the anticancer wonder drugs that could cure or, at the very least, curb the progression of various oncological diseases has regrettably failed to deliver. Severe side effects and low efficacy of IFN1-based pharmaceutics greatly limited use of these drugs and further reduced the enthusiasm of clinical oncologists for future optimization of IFN1-based therapeutic modalities. Incredibly, extensive clinical studies to assess the efficacy of IFN1 alone or in combination with other anticancer drugs have not been paralleled by an equal scope in defining the determinants that confer cell sensitivity or refractoriness to IFN1. Given that all effects of IFN1 on malignant and benign cells alike are mediated by its receptor, the mechanisms regulating these receptor cell surface levels should play a paramount role in shaping the magnitude and duration of IFN1-elicited effects. These mechanisms and their role in controlling IFN1 responses, as well as an ability of a growing tumor to commandeer these events, are the focus of our review. We postulate that activation of numerous signaling pathways leading to elimination of IFN1 receptor occurs in cancer cells and benign cells that contribute to tumor tissue. We further hypothesize that activation of these eliminative pathways enables the escape from IFN1-driven suppression of tumorigenesis and elicits the primary refractoriness of tumor to the pharmaceutical IFN1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847
The casein kinase 1 family: participation in multiple cellular processes in eukaryotes
Knippschild, U., Gocht, A., Wolff, S., Huber, N., Löhler, J., & Stöter, M. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2004.12.011 · Cited by 601
Cancer stem cell niche: the place to be
Borovski, T., De Sousa E Melo, F., Vermeulen, L., & Medema, J. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3220 · Cited by 518
Sitkovsky, M. V., Kjaergaard, J., Lukashev, D., & Ohta, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0229 · Cited by 253
De Pas, T., Toffalorio, F., Manzotti, M., Fumagalli, C., Spitaleri, G., Catania, C., Delmonte, A., Giovannini, M., Spaggiari, L., de Braud, F., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227e8c6 · Cited by 138
The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis
Redig, A. J., & Platanias, L. C. (2007) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2007.0007 · Cited by 51 · cited 1×
“However, the recruitment does not require the activation of TYK2 (Zheng and others 2011a), but may depend on some PKC species (our unpublished data) that are known to be induced by IFN1 (Redig and Platanias 2007).”
Cited by
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
m6A modification controls the innate immune response to infection by targeting type I interferons
Winkler, R., Gillis, E., Lasman, L., Safra, M., Geula, S., Soyris, C., Nachshon, A., Tai-Schmiedel, J., Friedman, N., Le-Trilling, V. T. K., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0275-z · Cited by 455
Klinkhammer, J., Schnepf, D., Ye, L., Schwaderlapp, M., Gad, H. H., Hartmann, R., Garcin, D., Mahlakõiv, T., & Staeheli, P. (2018) · eLife · doi:10.7554/elife.33354 · Cited by 264
Katlinski, K. V., Gui, J., Katlinskaya, Y. V., Ortiz, A., Chakraborty, R., Bhattacharya, S., Carbone, C. J., Beiting, D. P., Girondo, M. A., Peck, A. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.004 · Cited by 248
“Cell surface IFNAR1 levels are critical for all IFN effects (Fuchs, 2013; Uze et al., 2007).”
Self-citationKatlinskaya, Y. V., Katlinski, K. V., Yu, Q., Ortiz, A., Beiting, D. P., Brice, A., Davar, D., Sanders, C., Kirkwood, J. M., Rui, H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.006 · Cited by 108
“However, a tumor suppressive function of IFN in melanoma is not fully supported by available data from mice lacking the Ifnar1 receptor, which is required for all effects of IFN on cells (Fuchs, 2013; Piehler et al., 2012; Uze et al., 2007).”
BackgroundSelf-citationA BRISC-SHMT Complex Deubiquitinates IFNAR1 and Regulates Interferon Responses
Zheng, H., Gupta, V., Patterson-Fortin, J., Bhattacharya, S., Katlinski, K., Wu, J., Varghese, B., Carbone, C. J., Aressy, B., Fuchs, S. Y., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.025 · Cited by 101
BRCA1-A and BRISC: multifunctional molecular machines for ubiquitin signaling
Rabl, J. (2020) · Biomolecules · doi:10.3390/biom10111503 · Cited by 31
“IFNAR1 is an essential mediator of the human interferon response and a promising drug target [119].”
BackgroundProtection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Zhang, H., Tomar, V. S., Li, J., Basavaraja, R., Yan, F., Gui, J., McBrearty, N., Costich, T. L., Beiting, D. P., Blanco, M. A., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0295 · Cited by 13
“CellsurfacelevelsofIFNAR1,whichplaysa key role in all cell responses to IFN1 (20), are regulated by phosphorylation-dependent ubiquitination and subsequent degradation (21).”
BackgroundSelf-citation
Metadata
- Authors
- Fuchs, S. Y.
- Venue
- Journal of Interferon & Cytokine Research
- Publisher
- SAGE Publications
- Published
- 2013-04
- Volume
- 33
- Issue
- 4
- Pages
- 211-225
- ISSN
- 1079-9907 (ISSN-L)
- 1557-7465
- OpenAlex
- W2128511441
- Cited by
- 80
- References
- 9
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.